Administration of high doses of biologics under the skin will become the industry standard.[7] Phillips Medisize CEO Tony Bedford believes high-dose biologics will become the predominant choice for drugmakers.[7] More and more drugs are administered under the skin instead of intravenously.[7][3] The high-dose subcutaneous biologics market was valued at USD 92.6 billion in 2025 and is projected to grow to USD 211.4 billion by 2032 at a CAGR of 12.6%.[1] Subcutaneous administration of high doses, including up to 1000 mg, has enabled innovations in devices such as autoinjectors and wearable systems.[3][2] Manufacturing challenges include viscosity and stability of highly concentrated formulations.[1][2] This shift reduces the burden on patients and healthcare systems compared to intravenous infusions.[3]